ClinicalTrials.gg
Active, not recruitingNCT05646303Updated Aug 15, 2024

Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

A Phase 2 interventional study of Psilocybin and Placebo in Alcohol Use Disorder, sponsored by Clairvoyant Therapeutics. Active, not recruiting at 12 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Clairvoyant Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.
  • Registered 7 months after the study started (first participant enrolled May 2022, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Planned enrollment
3rd of 17
128 · median 62
Started
2022
the only one that year
Phase 2
16 of 17
7 open now
Primary completion
2024-08
later than 1 of 12 live
Registered
8th of 17
by date
Lead sponsor
1 of 17
Clairvoyant Therapeutics

Among the 17 studies testing psilocybin in Alcoholism, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 16 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 8th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question[s] it aims to answer are:

  • Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy?
  • Is treatment with psilocybin and therapy safe for participants?

Participants will

  • Attend 13 study visits
  • Take part in therapy sessions including 2 treatment sessions with either psilocybin or placebo
  • Record their daily alcohol consumption on study specific device

Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe diagnosis of AUD as measured by , 5th Edition (DSM-5) criteria using Structured Clinical Interview for DSM-5 by the investigator.
  • Expressed a wish to reduce or stop alcohol consumption.
  • Generally healthy with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, , urine analysis, and urine toxicology.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with or having a family history of any of the following concomitant psychiatric disorders: schizophrenia or prodromal symptoms, any bipolar disorder, obsessive compulsive disorder, or other psychotic episode. Recent (within last 12 months) diagnosis of a major depressive disorder (MDD) (HAM-D score >19), treatment resistant depression (TRD), post-traumatic stress disorder (PTSD), panic disorder, or eating disorders.
  • Subjects deemed unfit for psilocybin-assisted therapy based on the assessments made during psychotherapy sessions prior to the first psilocybin-assisted psychotherapy session.
  • History of hallucinogen use disorder, or any use in the past 1 year, or >25 lifetime uses.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Psilocybin

    2 oral doses of 25mg psilocybin capsules

    Drug: Psilocybin

  • Placebo comparator
    Placebo

    2 oral doses of placebo (microcrystalline cellulose) capsules

    Drug: Placebo

Interventions

  • Psilocybin and psychotherapy

  • DrugPlacebo

    Placebo and psychotherapy

06

What researchers measure

Primary outcomes

  1. Reduction in the number of Heavy Drinking Days

    Mean number of HDD from V5 (baseline) measured monthly (4 weeks) over the treatment period (Week 8), where heavy drinking is defined as the consumption of ≥60 g alcohol/day (if male) or ≥40 g alcohol/day (if female).

    Time frame: 8 weeks

07

Study locations

12 sites
  • Sabi Mind
    Calgary, Alberta T3C 0J7, Canada
  • Okanagan Clinical Trials
    Kelowna, British Columbia, Canada
  • Centre for Neurology Studies
    Surrey, British Columbia, Canada
  • University of British Columbia, Department of Psychiatry, BRAIN Lab
    Vancouver, British Columbia V6T 1Z3, Canada
  • Centricity Research
    Halifax, Nova Scotia B3S 1N2, Canada
  • MacAnxiety Research Centre
    Hamilton, Ontario L8S 1B7, Canada
  • Department of Psychiatry, Queen's University
    Kingston, Ontario, Canada
  • Centre for Addiction and Mental Health
    Toronto, Ontario M6J 1H4, Canada
  • Research Center Oxidi Oy / Addiktum Oy
    Helsinki, Finland
  • A-Klinikka
    Kouvola, 45100, Finland
  • Mentacare Oy
    Oulu, Finland
  • Addiktum Oy
    Turku, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Aug 2024, 27 months after the start.

Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 12, 2022
StartActual
May 2, 2022
Primary completionEst.
Aug 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05646303
Lead sponsor
Clairvoyant Therapeutics
Collaborators
Optimapharm
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
May 2, 2022
Primary completion
Aug 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Aug 15, 2024

Study contacts

Hannu Alho, MD
principal investigator · Addiktum Oy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion